Indivior raises 2026 guidance on record SUBLOCADE revenue

Indivior Pharmaceuticals reported second-quarter 2026 results on August 3, 2026, showing total net revenue of $343 million for the quarter ended June 30, 2026, up from $302 million a year earlier, a 14% increase¹. Total SUBLOCADE net revenue reached $253 million, up 21% year-over-year from $209 million¹, with U.S. SUBLOCADE net revenue up 22% to $238 million, driven by 18% dispense unit volume growth¹. New patient starts of 32,816 were a record¹, and by quarter end, more than 545,000 patients in the United States had been prescribed SUBLOCADE since its launch.

Profitability improved sharply. GAAP net income for the quarter was $122 million, or $0.98 per diluted share, compared to $18 million, or $0.14 per share, a year earlier¹. Adjusted EBITDA was $186 million, up 111% from $88 million in the prior-year quarter¹.

The company also disclosed capital return activity: Indivior repurchased 4,664,540 shares in the quarter at an average price of $37.52 for $175 million, bringing year-to-date repurchases to 8,638,693 shares for $300 million at an average price of $34.73¹.

Indivior raised its full-year 2026 outlook, moving net revenue guidance from a prior range of $1,215 million to $1,285 million up to $1,295 million to $1,365 million, total SUBLOCADE net revenue from $950 million to $990 million up to $1,010 million to $1,050 million, and adjusted EBITDA from $620 million to $660 million up to $700 million to $740 million¹.

On the corporate front, Indivior and Supernus Pharmaceuticals announced a definitive agreement to combine in an all-stock merger of equals to create a diversified, CNS-focused biopharmaceutical company¹. CEO Joe Ciaffoni said the company looks forward to closing the proposed merger with Supernus, expected in the fourth quarter¹.